Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For ...

Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company ...

Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.

The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic ...

AlphaQuest LLC reduced its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) by 79.8% during the fourth quarter, according to the company in its most recent 13F filing with the ...

Last May, the Food and Drug Administration (FDA) approved the company's second product, a vaccine for respiratory syncytial ...

As global markets grapple with inflation fluctuations and trade policy uncertainties, Asian tech stocks have emerged as a focal point for investors seeking growth opportunities amid broader market ...

Aprilia RSV1100 looks all set to make a comeback to the showroom floors, as the Italian motorcycle manufacturer has got a ...

Pfizer has been awarded breakthrough status from the FDA for its respiratory syncytial virus (RSV) vaccine in pregnant women, putting the company in pole position to bring a shot to market that ...

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...